A trio of big-name medical device makers are touting the results of clinical trials for several products designed to monitor or treat atrial fibrillation, stroke, thoracic and abdominal aortic aneurysms and unexplained fainting.
Clinical Trials
Clinical trials roundup: Medtronic study to boost CRT-D industry?
Cardiac resynchronization-therapy defibrillators reduced the mortality rate by 29 percent in patients with mild symptoms of heart failure, according to a study released by Medtronic Inc. (NYSE:MDT) at the annual meeting of the American Heart Assn. in Chicago.
Clinical trials roundup: FDA approves Medtronic trial of CoreValve implant
Here’s a roundup of recent clinical trial news:
Clinical trials roundup: Researchers say molecular imaging twice as effective in detecting breast cancer
Here’s a roundup of recent clinical trial news:
Clinical trials roundup
Here’s a roundup of recent clinical trial news:
Boston Scientific, St. Jude Medical detail clinical studies
Boston Scientific Corp. (NYSE:BSX) and St. Jude Medical Inc. (NYSE:STJ) released details on a pair of clinical trials, one for implantable cardiac defibrillators and another for transcatheter aortic valves.
The scientists conducting the BSX-funded study, who published their work in the journal Circulation, found that one life is saved for every eight patients who receive an ICD and that there is a 34 percent "relative reduction in the risk of death" for ICD patients at eight years.
Cordis: Our 10-year-old Cypher’s still as good as Abbott’s Xience V
Cordis Corp., the stent-making subsidiary of Johnson & Johnson (NYSE:JNJ), put a cap on the 2010 Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., with a final volley in the stent wars: A study indicating that its venerable Cypher stent is just as safe and effective as the market-leading Xience V made by rival Abbott (NYSE:ABT).
TCT 2010 roundup: Abbott keeps after Boston Scientific’s Taxus
Abbott (NYSE:ABT) kept up the pressure on Boston Scientific Corp. (NYSE:BSX) at a high-profile cardiology conference, releasing data from a pair of studies it says show that its Xience V drug-eluting stent is better than Boston Scientific’s competing Taxus.
Two-year data from the head-to-head trials of the paclitaxel-eluting Taxus against the everolimus-eluting Xience stent showed that more patients treated with BSX’s stent developed late-stent thrombosis. The data were presented in Washington, D.C., at the annual Transcatheter Cardiovascular Therapeutics conference.
MYTHOS RenalGuard Trial Demonstrates Greater Efficacy Than Current Standard of Care
PRESS RELEASE
PLC Systems Inc. (OTC:PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that updated results from the MYTHOS investigator-sponsored clinical trial of RenalGuard in Italy showed that RenalGuard was more effective than the current standard of care at preventing Contrast Induced-Nephropathy (CIN). In scientifically significant results presented at Transcatheter Cardiovascular Therapeutics (TCT) 2010, the investigators found that patients treated with RenalGuard developed CIN, a serious and potentially fatal condition, at much lower rates than patients in the control group who were treated with overnight hydration, the current gold standard therapy.
LEADERS Three-Year Results Suggest Improved Safety and Efficacy of BioMatrix Flex over Cypher Select
PRESS RELEASE
Biosensors International Group, Ltd ("Biosensors", "Company", BIG:SP) today announced three-year results of the LEADERS trial, which showed a continuing positive trend towards a safety and efficacy benefit for BioMatrix Flex, Biosensors’ Biolimus A9-eluting stent system with abluminal biodegradable polymer, compared to Cypher Select, Johnson & Johnson’s sirolimus-eluting stent system with a durable polymer. Results were presented by Professor Patrick W. Serruys, Erasmus Medical Center, Netherlands, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
Novel Drug-Eluting Stent System for Treatment of Small Vessels Demonstrated Safe and Effective at Eight Months
PRESS RELEASE
Biosensors International Group, Ltd ("Biosensors", "Company", BIG:SP) today announced 8-month results from the CARE II Study, which showed that its novel Sparrow drug-eluting stent system, developed by recently-acquired CardioMind, Inc., is both safe and effective in the treatment of small vessel lesions. These results were presented by the Principal Investigator, Dr. Alexandre Abizaid, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, at the 22nd annual Transcatheter Cardiovascular Therapeutics ("TCT") scientific symposium, sponsored by the Cardiovascular Research Foundation.